In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Generics
The Russian drugmaker Geropharm has demanded a compulsory license from Denmark’s Novo Nordisk to produce a generic of Ozempic (semaglutide), which is a drug used for diabetes and the active ingredient is marketed as Wegovy for weight loss, reports The Pharma Letter’s local correspondent. 12 July 2024
Generics
GlaxoSmithKline Trading, the distribution division of the British pharma major GSK, has filed a complaint to the Russian anti-trust regulator FAS on the recent auction for state procurements of GSK’s anti-HIV drug Tivicay (dolutegravir). 12 July 2024
Pharmaceutical
As part of an ongoing organizational restructuring effort, Swiss pharma giant Novartis (NOVN: VX) will reportedly close an R&D site in San Diego, USA, leading to job losses. 12 July 2024
Pharmaceutical
Phesi, a clinical development analytics company, has released its mid-year analysis for 2024. 11 July 2024
Biotechnology
Efforts to end US business deals with certain foreign biotechs considered threats are gaining traction again, with House Speaker Mike Johnson stating his intention to hold a vote on the BIOSECURE act this year. 11 July 2024
Biotechnology
Henry Pelish has continued his rise up the ranks at Nuvalent, a Boston-based biopharma focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. 11 July 2024
Biotechnology
CureLab Oncology has appointed Aubrey Galloway as chief medical officer. 11 July 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Fast Track designation for AB-1005, which is being developed for moderate Parkinson’s disease by German pharma major Bayer gene therapy subsidiary Asklepios BioPharmaceutical (AskBio). 11 July 2024
Biotechnology
French drugmaker Ipsen has entered into an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential, from China-based Foreseen Biotechnology. 11 July 2024
Biotechnology
German drug discovery and development company Evotec has entered into a multi-year master research collaboration and option and license agreement with US pharma giant Pfizer. 11 July 2024
Pharmaceutical
Shares of US pharma giant Pfizer were up more than 3% at $29.25 pre-market, as the company announced progress in its attempt to play a role in the fast-growing obesity sector. 11 July 2024
Pharmaceutical
French pharma major Sanofi has started shipping its first influenza vaccines across the USA in preparation for the 2024/25 flu season. 11 July 2024
Pharmaceutical
US drugmaker AbbVie has announced that Roopal Thakkar, who currently serves as senior vice president, chief medical officer, global therapeutics, has been appointed to the position of executive vice president, research and development, and chief scientific officer (CSO). 10 July 2024
Pharmaceutical
UK-headquartered clinical-stage company OKYO Pharma’s today shared promising new categorical data analyses from the recent OK-101 Phase II trial in dry eye disease (DED) patients. 10 July 2024
Pharmaceutical
The Sustainable Medicines Partnership (SMP), a collaborative of 48 organizations in the pharmaceutical and healthcare sectors, has published a report into wasted medicines. 10 July 2024
Pharmaceutical
IDEAYA Biosciences (Nasdaq: IDYA) has announced a plan to raise about $263 million in a public share offering, which is expected to close around 11 July. 10 July 2024
Pharmaceutical
Global growth in the pharma market will reach 7.7% through to the end of the decade, according to an analysis from industry commentator Evaluate. 10 July 2024
Biotechnology
Cambridge, USA-based biotech incubator Flagship Pioneering today announced it has expanded its capital base by $3.6 billion. 10 July 2024
Biotechnology
Lisbon-based Biovance Capital Partners, Portugal’s leading life sciences venture capital (VC) firm, has announced the first closing of its new biotech fund. 10 July 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze